<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2786">
  <stage>Registered</stage>
  <submitdate>24/05/2010</submitdate>
  <approvaldate>24/05/2010</approvaldate>
  <nctid>NCT01131000</nctid>
  <trial_identification>
    <studytitle>Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients</studytitle>
    <scientifictitle>A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial To Evaluate The Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Adult Febrile Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CPI-CL-004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fever</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ibuprofen
Treatment: drugs - Ibuprofen
Treatment: drugs - Ibuprofen
Other interventions - Normal Saline

Experimental: Ibuprofen - 

Placebo Comparator: Saline - Normal Saline


Treatment: drugs: Ibuprofen
Intravenous ibuprofen, 100 mg, Single-dose

Treatment: drugs: Ibuprofen
Intravenous ibuprofen, 200mg, single dose

Treatment: drugs: Ibuprofen
Intravenous ibuprofen, 400 mg, Single-dose

Other interventions: Normal Saline
Normal Saline, 100 ml, Single-dose

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percent of patients with fever reduction to less than 101.0 degree fahrenheit following a single dose of intravenous ibuprofen.</outcome>
      <timepoint>4 hours</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Be hospitalized

          2. Have new (not chronic, within last 7 days) onset of fever, documented by temperature
             greater than or equal to 101.0ºF (38.3ºC)

          3. Have adequate intravenous access

          4. Have the ability to understand the requirements of the study, be willing to provide
             written informed consent (as evidenced by signature on an informed consent document
             approved by an Institutional Review Board), and agree to abide by the study
             restrictions and to return for the required assessments</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Be less than 18 years of age

          2. Have received antipyretic drug therapy (e.g., aspirin, other NSAIDs, or acetaminophen)
             within 4 hours before dosing

          3. Have any history of allergy or hypersensitivity to any component of IVIb, NSAIDs
             (including aspirin), or COX-2 inhibitors

          4. Be pregnant or nursing

          5. Have a history of severe head trauma that required current hospitalization,
             intracranial surgery, or stroke within the previous 30 days, or any history of
             intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system
             mass lesions

          6. Weigh less than 40 kg

          7. Have a history of congenital bleeding diatheses (e.g., hemophilia) or any active
             clinically significant bleeding, or have underlying platelet dysfunction, including
             (but not limited to) idiopathic thrombocytopenic purpura, disseminated intravascular
             coagulation, or congenital platelet dysfunction

          8. Have gastrointestinal bleeding that has required medical intervention within the
             previous 6 weeks (unless definitive surgery has been performed)

          9. Have a platelet count less than 30,000/mm3

         10. Be receiving full dose anticoagulation therapy

         11. Have fever secondary to blood or drug reaction

         12. Have an expected life span of less than 14 days because of imminent withdrawal of life
             support or severity of illness

         13. Be receiving treatment with corticosteroids (Patients who are expected to receive
             corticosteroids during the Treatment Period or through Hour 120 of the Post-treatment
             Period are not eligible.)

         14. Have neurogenic fever

         15. Be on dialysis, have oliguria or creatinine greater than 3.0 mg/dL, or be receiving
             nephrotoxic drugs

         16. Have had major surgery within the past 12 hours, unless adequate hemostasis has been
             achieved

         17. Have received another investigational drug within the past 30 days

         18. Become afebrile (temperature below 101.0ºF [38.3ºC]) before dosing and not redevelop
             fever entry criteria during this hospitalization

         19. Be otherwise unsuitable for the study, in the opinion of the Investigator</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>123</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA</recruitmentstate>
    <hospital>Newcastle Mater Misericordiae Hospital - New Lambton</hospital>
    <hospital>Flinders Medical Centre - Adelaide</hospital>
    <postcode>2305 - New Lambton</postcode>
    <postcode> - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cumberland Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to evaluate the efficacy of intravenous ibuprofen on
      reducing fever at 4 hours.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01131000</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gordon Bernard, M.D.</name>
      <address>Cumberland Pharmaceuticals Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>